Piramal Pharma Limited Stock Price Today (NSE: PPLPHARMA)
Fundamental Score
Piramal Pharma Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Piramal Pharma Limited share price today is ₹202.37, down 0.54% on NSE/BSE as of 16 September 2026. Piramal Pharma Limited (PPLPHARMA) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹26.86K (Cr). The 52-week high for PPLPHARMA share price is ₹231.93 and the 52-week low is ₹132.30. The company has a Return on Equity (ROE) of -4.00% and a debt-to-equity ratio of 0.67.
Piramal Pharma Limited Share Price Chart — NSE/BSE Historical Performance
Piramal Pharma Limited share price chart: 6.09% return over the past month. 52-week high ₹231.93, 52-week low ₹132.30.
Piramal Pharma Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹203.00 | ₹207.96 | ₹198.86 | ₹202.37 | 29.67L (Cr) | |
| ₹211.07 | ₹211.35 | ₹202.55 | ₹203.47 | 31.04L (Cr) | |
| ₹210.59 | ₹214.45 | ₹208.68 | ₹211.35 | 34.09L (Cr) | |
| ₹218.00 | ₹218.99 | ₹211.81 | ₹212.49 | 27.26L (Cr) | |
| ₹227.00 | ₹227.75 | ₹217.10 | ₹218.00 | 38.82L (Cr) | |
| ₹220.65 | ₹231.93 | ₹220.37 | ₹226.62 | 210.40L (Cr) | |
| ₹214.23 | ₹221.80 | ₹213.12 | ₹219.66 | 64.07L (Cr) | |
| ₹214.99 | ₹217.00 | ₹210.52 | ₹214.22 | 26.18L (Cr) | |
| ₹214.93 | ₹216.90 | ₹211.81 | ₹214.49 | 25.39L (Cr) | |
| ₹212.84 | ₹217.82 | ₹211.36 | ₹213.78 | 31.02L (Cr) |
Piramal Pharma Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹215.00 | ₹231.93 | ₹198.86 | ₹202.37 | -5.87% | |
| ₹196.36 | ₹220.36 | ₹193.03 | ₹214.40 | +9.19% | |
| ₹168.68 | ₹202.26 | ₹166.11 | ₹195.61 | +15.97% | |
| ₹172.99 | ₹175.95 | ₹158.10 | ₹168.09 | -2.83% | |
| ₹161.87 | ₹196.44 | ₹157.77 | ₹172.79 | +6.75% | |
| ₹140.00 | ₹171.65 | ₹136.26 | ₹161.87 | +15.62% | |
| ₹152.62 | ₹160.54 | ₹132.30 | ₹136.54 | -10.54% | |
| ₹152.40 | ₹169.54 | ₹149.76 | ₹156.13 | +2.45% | |
| ₹172.75 | ₹185.04 | ₹148.31 | ₹154.68 | -10.46% | |
| ₹187.90 | ₹189.20 | ₹165.12 | ₹172.21 | -8.35% | |
| ₹199.76 | ₹209.25 | ₹184.20 | ₹187.21 | -6.28% | |
| ₹191.07 | ₹206.60 | ₹190.52 | ₹199.63 | +4.48% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Piramal Pharma Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Piramal Pharma Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of PPLPHARMA across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Strong Operating Margins (15.05%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Strong Revenue Growth (17.39%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Healthy Liquidity Position (Current Ratio: 1.54)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹679.04 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Strong Institutional Confidence (FII+DII: 45.78%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Below-Average Return on Equity (-4.00%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (0.86%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-15.07%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Interest Coverage (0.32x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Piramal Pharma Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Piramal Pharma Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Piramal Pharma LimitedPiramal Pharma ...Selected✓ PPLPHARMA • 543635 | 8.2/100 | ₹202.37₹202 | ₹26861.58₹26861.58 | — — | -4.00%Poor -4.00% Poor | 0.86%Poor 0.86% Poor | 0.67Good 0.7 Good | — — | 7.03%Good 7.03% Good | 0.08% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9467.50₹9468 | ₹250888.75₹250888.75 | 85.90Average 85.9 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4939.50₹4940 | ₹167182.32₹167182.32 | 78.91Average 78.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1371.90₹1372 | ₹110828.94₹110828.94 | 32.87Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1941.10₹1941 | ₹104867.93₹104867.93 | 95.81Average 95.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1683.00₹1683 | ₹96839.82₹96839.82 | 26.30Average 26.3 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.70₹2101 | ₹96054.51₹96054.51 | 17.36Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1144.50₹1145 | ₹95565.75₹95565.75 | 29.58Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2293.70₹2294 | ₹94729.81₹94729.81 | 46.35Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price250888.75 Cr
- Torrent Pharmaceuticals Limited share price167182.32 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110828.94 Cr
Piramal Pharma Limited PE Ratio History
Historical price-to-earnings ratio for PPLPHARMA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹0.68 | ₹172.21 | 253.3x |
| FY 2024 | ₹0.14 | ₹266.25 | 1901.8x |
| FY 2022 | ₹3.09 | ₹111.96 | 36.2x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Piramal Pharma Limited Dividend History
Annual cash dividends paid by PPLPHARMA — dividend yield 0.08%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹14.47 Cr |
| FY 2023 | ₹67.00 Cr |
| FY 2022 | ₹50.00 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Piramal Pharma Limited Quarterly Performance
Latest quarterly metrics for PPLPHARMA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
17.39%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-15.07%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
7.03%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Piramal Pharma Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for PPLPHARMA — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Piramal Pharma Limited Financial Statements
Annual income statement, balance sheet and cash flow for Piramal Pharma Limited (PPLPHARMA) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Piramal Pharma Limited
About PPLPHARMA (Piramal Pharma Limited)
Piramal Pharma Ltd is a dynamic force within the global pharmaceutical landscape, carving a niche as an integrated solutions provider. From its strategic base in India, the company... orchestrates a multifaceted approach encompassing research, development, and the manufacturing of both active pharmaceutical ingredients (APIs) and finished dosage forms. PPLPHARMA distinguishes itself through a commitment to innovation, evident in its pursuit of novel drug delivery systems and specialized formulations designed to address unmet medical needs. This commitment extends beyond its own product portfolio, as PPLPHARMA actively engages in collaborative partnerships with pharmaceutical companies worldwide, leveraging its expertise and infrastructure to accelerate the advancement of promising therapeutic candidates. Through a relentless focus on quality and efficiency, the company is positioned as a trusted partner in the ever-evolving world of healthcare. The company's operational model is built upon a foundation of advanced manufacturing capabilities and stringent regulatory compliance. With a network of state-of-the-art facilities strategically located across various geographies, Piramal Pharma Ltd offers a seamless, end-to-end solution for pharmaceutical companies seeking to outsource key stages of their drug development and manufacturing processes. This comprehensive offering spans from early-stage research and development to late-stage commercial production, ensuring that clients receive tailored support every step of the way. PPLPHARMA emphasizes sustainability in its operations, reflecting a commitment to responsible manufacturing practices and environmental stewardship. This holistic approach, combined with its unwavering focus on customer satisfaction, solidifies the company's reputation as a reliable and ethical partner within the industry. Beyond its core contract development and manufacturing (CDMO) services, Piramal Pharma Ltd also maintains a growing portfolio of proprietary pharmaceutical products targeting specific therapeutic areas. These branded offerings are distributed through a robust global network, enabling the company to directly impact patient outcomes and improve healthcare access. PPLPHARMA’s dedication to innovation and quality is underscored by its ongoing investment in research and development, constantly exploring new avenues for therapeutic advancement and operational efficiency. The company’s forward-looking vision positions it as a key player in shaping the future of pharmaceutical manufacturing and healthcare delivery, driven by a commitment to excellence and a passion for improving lives worldwide.
Company Details
Key Leadership
PPLPHARMA Share Price: Frequently Asked Questions
What is the current share price of Piramal Pharma Limited?
Piramal Pharma Limited (PPLPHARMA) trades at ₹202.37 on NSE and BSE. Market cap ₹26.86K (Cr). Educational data only.
What is the P/E ratio of Piramal Pharma Limited?
Piramal Pharma Limited has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for Piramal Pharma Limited?
Piramal Pharma Limited has a Bull Run score of 8.2/100 based on 25+ financial parameters.
Does Piramal Pharma Limited pay dividends?
Piramal Pharma Limited has a dividend yield of 0.08%. Past dividends don't guarantee future payments.
What is the ROE of Piramal Pharma Limited?
Piramal Pharma Limited has ROE of -4.00%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Piramal Pharma Limited?
Piramal Pharma Limited has debt-to-equity of 0.67.
Is Piramal Pharma Limited a good investment?
Bull Run gives Piramal Pharma Limited a score of 8.2/100. This is not investment advice — consult a SEBI-registered advisor.